MX344355B - Uso de inhibidores de erbb3 en el tratamiento de canceres de mama triple negativos y de tipo basal. - Google Patents
Uso de inhibidores de erbb3 en el tratamiento de canceres de mama triple negativos y de tipo basal.Info
- Publication number
- MX344355B MX344355B MX2012010226A MX2012010226A MX344355B MX 344355 B MX344355 B MX 344355B MX 2012010226 A MX2012010226 A MX 2012010226A MX 2012010226 A MX2012010226 A MX 2012010226A MX 344355 B MX344355 B MX 344355B
- Authority
- MX
- Mexico
- Prior art keywords
- basal
- triple negative
- erbb3
- patient
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a métodos para suprimir el crecimiento de tumores de mama triple negativos y tumores de mama de tipo basal al poner en contacto las células tumorales con un inhibidor de ErbB3, por ej., un anticuerpo anti-ErbB3. También se proporcionan métodos para tratar el cáncer de mama triple negativo o cáncer de mama de tipo basal en un paciente mediante la administración al paciente de un inhibidor de ErbB3, por ej., un anticuerpo antiErbB3. Los métodos de tratamiento pueden comprender además seleccionar un paciente que tiene un cáncer de mama triple negativo o un cáncer de mama de tipo basal y luego administrar un inhibidor de ErbB3 al paciente. Los métodos de tratamiento también pueden comprender administrar al menos un agente anticanceroso adicional al paciente en combinación con el inhibidor de ErbB3.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31289510P | 2010-03-11 | 2010-03-11 | |
PCT/US2011/028129 WO2011112953A2 (en) | 2010-03-11 | 2011-03-11 | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2012010226A MX2012010226A (es) | 2013-01-29 |
MX344355B true MX344355B (es) | 2016-12-14 |
Family
ID=44513103
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012010226A MX344355B (es) | 2010-03-11 | 2011-03-11 | Uso de inhibidores de erbb3 en el tratamiento de canceres de mama triple negativos y de tipo basal. |
Country Status (21)
Country | Link |
---|---|
US (4) | US8895001B2 (es) |
EP (2) | EP2544680B1 (es) |
JP (2) | JP2013522237A (es) |
KR (1) | KR101798679B1 (es) |
CN (1) | CN102858335B (es) |
AU (1) | AU2011224186C1 (es) |
BR (1) | BR112012022802A2 (es) |
CA (1) | CA2792327C (es) |
DK (1) | DK2544680T3 (es) |
EA (1) | EA201201186A1 (es) |
ES (1) | ES2535503T3 (es) |
HK (1) | HK1174254A1 (es) |
IL (1) | IL221693A (es) |
MX (1) | MX344355B (es) |
NZ (1) | NZ602084A (es) |
PL (1) | PL2544680T3 (es) |
PT (1) | PT2544680E (es) |
SG (1) | SG183532A1 (es) |
UA (1) | UA111149C2 (es) |
WO (1) | WO2011112953A2 (es) |
ZA (1) | ZA201206425B (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2716301T (pt) * | 2007-02-16 | 2017-07-04 | Merrimack Pharmaceuticals Inc | Anticorpos contra erbb3 e suas utilizações |
CA2740900C (en) | 2008-11-03 | 2019-09-24 | Alethia Biotherapeutics Inc. | Antibodies that specifically block the biological activity of a tumor antigen |
AU2010335282B2 (en) | 2009-12-22 | 2015-05-21 | Roche Glycart Ag | Anti-HER3 antibodies and uses thereof |
PL2544680T3 (pl) * | 2010-03-11 | 2015-08-31 | Merrimack Pharmaceuticals Inc | Zastosowanie inhibitorów ERBB1 w leczeniu potrójnie ujemnego raka gruczołu sutkowego |
DK2606070T3 (en) | 2010-08-20 | 2017-03-27 | Novartis Ag | Antibodies for the epidermal growth factor receptor 3 (HER3) |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
EA201300996A1 (ru) * | 2011-03-11 | 2014-01-30 | Мерримак Фармасьютикалс, Инк. | Использование ингибиторов рецепторов семейства egfr в лечении гормонорезистентного рака молочной железы |
EP2691421B1 (en) | 2011-03-31 | 2016-11-09 | Alethia Biotherapeutics Inc. | Antibodies against kidney associated antigen 1 and antigen binding fragments thereof |
KR20140063578A (ko) * | 2011-06-30 | 2014-05-27 | 메리맥 파마슈티컬즈, 인크. | 부인과 암들의 치료를 위해 파크리탁셀과 조합한 항-erbb3 항체들 |
US9273143B2 (en) | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
US8791244B2 (en) | 2011-09-30 | 2014-07-29 | Regeneron Pharmaceuticals, Inc. | Anti-ErbB3 antibodies and uses thereof |
EP3974832A1 (en) * | 2011-10-06 | 2022-03-30 | Aveo Pharmaceuticals, Inc. | Predicting tumor response to anti-erbb3 antibodies |
WO2013056248A2 (en) | 2011-10-13 | 2013-04-18 | The Regents Of The University Of California | Treatment of breast cancer with companion diagnostic |
RU2620068C2 (ru) | 2011-11-23 | 2017-05-22 | МЕДИММЬЮН, ЭлЭлСи | Связывающие молекулы, специфичные по отношению к her3, и их применения |
ES2758433T3 (es) * | 2011-12-05 | 2020-05-05 | Novartis Ag | Anticuerpos contra el receptor 3 del factor de crecimiento epidérmico (HER3) |
EP2802351B1 (en) | 2012-01-09 | 2019-03-27 | ADC Therapeutics SA | Agents for treating triple negative breast cancer |
WO2013155346A1 (en) | 2012-04-11 | 2013-10-17 | The Regents Of The University Of California | Diagnostic tools for response to 6-thiopurine therapy |
US20150266970A1 (en) * | 2012-10-24 | 2015-09-24 | Yeda Research And Development Co. Ltd. | Combinations of epidermal growth factor receptor targeting antibodies for treating cancer |
EP2928488A1 (en) | 2012-12-07 | 2015-10-14 | The General Hospital Corporation | Combinations of a pi3k/akt inhibitor compound with an her3/egfr inhibitor compound and use thereof in the treatment of a hyperproliferative disorder |
AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
WO2015048008A2 (en) | 2013-09-24 | 2015-04-02 | Medimmune, Llc | Binding molecules specific for her3 and uses thereof |
WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
US20170173005A1 (en) * | 2014-03-27 | 2017-06-22 | Research Foundation Of The City University Of New York | Method for detecting or treating triple negative breast cancer |
WO2015157634A1 (en) | 2014-04-11 | 2015-10-15 | Kolltan Pharmaceuticals, Inc. | Anti-erbb antibodies and methods of use thereof |
CA2983008A1 (en) | 2015-04-17 | 2016-10-20 | Merrimack Pharmaceuticals, Inc. | Combination treatments with seribantumab |
US9795624B2 (en) | 2015-05-04 | 2017-10-24 | Research Foundation Of The City University Of New York | Cationic polymers as co-drugs for chemotherapeutic agents |
US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
JP6823055B2 (ja) | 2015-06-15 | 2021-01-27 | アンジオケム インコーポレーテッド | 軟髄膜癌腫症の治療方法 |
CN105375955B (zh) * | 2015-10-26 | 2018-07-17 | 西安电子科技大学 | 一种信能同传中继网络中的协作传输方法 |
KR101746152B1 (ko) | 2015-12-07 | 2017-06-13 | 주식회사 이수앱지스 | ErbB3에 특이적으로 결합하는 항체 및 그의 용도 |
JP2018536682A (ja) | 2015-12-11 | 2018-12-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Egfr及び/またはerbb3遮断に耐性のある腫瘍の成長を低減または防止するための方法 |
AU2017235450A1 (en) | 2016-03-15 | 2018-08-16 | Merrimack Pharmaceuticals, Inc. | Methods for treating ER+, HER2-, HRG+ breast cancer using combination therapies comprising an anti-ErbB3 antibody |
KR101923641B1 (ko) * | 2016-11-25 | 2018-11-29 | 재단법인 목암생명과학연구소 | 항her3 항체 및 이를 포함하는 암 예방 또는 치료용 조성물 |
EP3595636A4 (en) | 2017-03-16 | 2021-01-13 | Children's Medical Center Corporation | GENETICALLY PRODUCED LIPOSOMES AS TARGETED THERAPEUTICS AGAINST CANCER |
WO2019185164A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Her3 antigen-binding molecules |
AU2019364258A1 (en) * | 2018-10-21 | 2021-06-03 | Slsg Limited Llc | Combination immunotherapy for treatment of triple-negative breast cancer |
WO2020161614A1 (en) * | 2019-02-05 | 2020-08-13 | Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet) | Methods for treating triple negative breast cancer using a human erbb-2 mutant protein |
CN112755173B (zh) * | 2020-12-31 | 2022-01-07 | 深圳市科达顺生物技术有限公司 | 用于治疗三阴性乳腺癌的Ii-Key/HER2杂交多肽药物及其制备方法 |
JP2024509914A (ja) * | 2021-03-11 | 2024-03-05 | エレベーション オンコロジー, インコーポレイテッド | ニューレグリン1(nrg1)遺伝子融合に関連する腫瘍を処置するための抗erbb3(her3)モノクローナル抗体の投与量および投与 |
Family Cites Families (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5344760A (en) | 1991-06-03 | 1994-09-06 | Ciba Corning Diagnostics Corp. | Method of cancer detection |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US6983227B1 (en) | 1995-01-17 | 2006-01-03 | Intertech Ventures, Ltd. | Virtual models of complex systems |
EP0873363B1 (en) | 1995-06-14 | 2010-10-06 | The Regents of The University of California | High affinity human antibodies to tumor antigens |
BR9708343A (pt) | 1996-03-27 | 1999-08-03 | Genentech Inc | Anticorpo composição linhagem de células método para determinar a presença de proteína de erbB3 e kit |
US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
DE69740038D1 (es) | 1996-07-12 | 2010-12-16 | Genentech Inc | |
US6255455B1 (en) | 1996-10-11 | 2001-07-03 | The Trustees Of The University Of Pennsylvania | Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof |
US20020002276A1 (en) | 1997-02-10 | 2002-01-03 | Genentech, Inc. | Chimeric heteromultimer adhesins |
US6417168B1 (en) | 1998-03-04 | 2002-07-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods of treating tumors |
GB2336695A (en) | 1998-04-20 | 1999-10-27 | Teamware Group Oy | Modelling a work process |
MXPA00011248A (es) | 1998-05-15 | 2004-09-06 | Imclone Systems Inc | Tratamientos de tumores humanos con radiacion e inhibidores de tirosina cinasas de recptor de factor de crecimiento. |
AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
KR20090024308A (ko) | 1999-08-27 | 2009-03-06 | 제넨테크, 인크. | 항-ErbB2 항체 투여 치료 방법 |
US7390632B2 (en) | 1999-09-30 | 2008-06-24 | Tumor Biology Investment Group, Inc. | Soluble ErbB3 receptor isoforms |
US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
AU2001262943A1 (en) | 2000-04-14 | 2001-10-30 | Metabolon, Inc. | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
JP2003534292A (ja) | 2000-05-19 | 2003-11-18 | ジェネンテック・インコーポレーテッド | Erbbアンタゴニスト癌治療に対する有効な応答の可能性を向上させるための遺伝子検出アッセイ |
US20020119148A1 (en) | 2000-09-01 | 2002-08-29 | Gerritsen Mary E. | ErbB4 antagonists |
US6871171B1 (en) | 2000-10-19 | 2005-03-22 | Optimata Ltd. | System and methods for optimized drug delivery and progression of diseased and normal cells |
EP1228766A1 (en) | 2001-01-31 | 2002-08-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | PYK2 phosphorylation by HER3 induces tumor invasion |
PT1392359E (pt) * | 2001-05-11 | 2010-01-27 | Ludwig Inst For Cancer Res Ltd | Proteínas de ligação específica e suas utilizações |
US7638302B2 (en) | 2001-05-31 | 2009-12-29 | Tumor Biology Investment Group, Inc. | Soluble ErbB3 receptor isoforms |
US7125680B2 (en) | 2001-07-27 | 2006-10-24 | The Regents Of The University Of California | Methods and materials for characterizing and modulating interaction between heregulin and HER3 |
JP2005508887A (ja) | 2001-08-03 | 2005-04-07 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション | Egf受容体の結晶構造に基づいたスクリーニング方法 |
WO2003012072A2 (en) | 2001-08-03 | 2003-02-13 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies to activated erbb family members and methods of use thereof |
EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
CA2462502A1 (en) | 2001-10-19 | 2003-05-15 | Pharma Mar, S.A. | Improved use of antitumoral compound in cancer therapy |
US7415359B2 (en) | 2001-11-02 | 2008-08-19 | Gene Network Sciences, Inc. | Methods and systems for the identification of components of mammalian biochemical networks as targets for therapeutic agents |
AU2003218600C1 (en) | 2002-03-26 | 2009-12-17 | Zensun (Shanghai) Science & Technology Co., Ltd. | ERBB3 based methods and compositions for treating neoplasms |
US20040248151A1 (en) | 2002-04-05 | 2004-12-09 | Ventana Medical Systems, Inc. | Method for predicting the response to HER2-directed therapy |
US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
US20040229380A1 (en) | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB heterodimers as biomarkers |
AU2003251597A1 (en) | 2002-06-19 | 2004-01-06 | Abgenix, Inc. | Method for predicting response to epidermal growth factor receptor-directed therapy |
ATE328906T1 (de) | 2002-06-28 | 2006-06-15 | Domantis Ltd | Dual-specifische liganden mit erhöhter halbwertszeit |
WO2004053497A2 (en) | 2002-12-11 | 2004-06-24 | Ventana Medical Systems, Inc. | Method for predicting the response to her2-directed therapy |
EP1613961A4 (en) | 2003-04-01 | 2007-03-07 | Monogram Biosciences Inc | SURFACE RECEPTOR COMPLEXES AS BIOMARKERS |
WO2005014618A2 (en) | 2003-08-08 | 2005-02-17 | Immunomedics, Inc. | Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
US20070059785A1 (en) | 2003-08-15 | 2007-03-15 | Smithkline Beecham Corporation | Biomarkers in cancer |
US8554486B2 (en) | 2004-02-20 | 2013-10-08 | The Mathworks, Inc. | Method, computer program product, and apparatus for selective memory restoration of a simulation |
ES2741546T3 (es) | 2004-03-31 | 2020-02-11 | Massachusetts Gen Hospital | Método para determinar la respuesta del cáncer a tratamientos dirigidos al receptor del factor de crecimiento epidérmico |
AU2005249396B2 (en) | 2004-05-05 | 2011-10-20 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents for modulating biological activity |
EP1751309B1 (en) | 2004-05-27 | 2015-07-22 | The Regents of The University of Colorado | Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients |
US7794960B2 (en) | 2004-06-04 | 2010-09-14 | Glaxosmithkline Llc | Predictive biomarkers in cancer therapy |
US7329737B2 (en) | 2004-08-03 | 2008-02-12 | Dyax Corp. | Antibodies that bind hK-1 |
WO2006017859A2 (en) | 2004-08-06 | 2006-02-16 | Genentech, Inc. | Assays and methods using biomarkers |
WO2006020706A2 (en) | 2004-08-12 | 2006-02-23 | Dyax Corp. | Tie complex binding proteins |
US20060136139A1 (en) | 2004-10-12 | 2006-06-22 | Elcock Adrian H | Rapid computational identification of targets |
US20080254497A1 (en) | 2004-10-15 | 2008-10-16 | Monogram Biosciences, Inc. | Response Predictors for Erbb Pathway-Specific Drugs |
AU2005314127A1 (en) | 2004-12-07 | 2006-06-15 | Genentech, Inc. | Selecting patients for therapy with a HER inhibitor |
US7862995B2 (en) | 2004-12-10 | 2011-01-04 | Targeted Molecular Diagnostics | Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor |
CN101163501A (zh) | 2005-02-23 | 2008-04-16 | 梅里麦克制药股份有限公司 | 调节生物活性的双特异性结合剂 |
WO2006096861A2 (en) | 2005-03-08 | 2006-09-14 | Genentech, Inc. | METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs) |
US20090061422A1 (en) | 2005-04-19 | 2009-03-05 | Linke Steven P | Diagnostic markers of breast cancer treatment and progression and methods of use thereof |
US20090298061A1 (en) | 2005-07-29 | 2009-12-03 | Siemens Healthcare Diagnostics Inc. | Diagnostic Methods for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapy |
WO2007041502A2 (en) | 2005-09-30 | 2007-04-12 | Monogram Biosciences | Methods for determining responsiveness to cancer therapy |
JP2009511008A (ja) | 2005-10-05 | 2009-03-19 | アストラゼネカ ユーケー リミテッド | ErbB受容体薬に対する患者の応答を予測またはモニタリングする方法 |
AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
US7908091B2 (en) | 2006-03-17 | 2011-03-15 | Prometheus Laboratories Inc. | Methods of predicting and monitoring tyrosine kinase inhibitor therapy |
WO2007115571A2 (en) | 2006-04-07 | 2007-10-18 | Enkam Pharmaceuticals A/S | Erbb receptor-derived peptide fragments |
JP5048757B2 (ja) | 2006-05-05 | 2012-10-17 | イェール・ユニバーシティー | 診断指標または予測指標としての細胞内局在プロフィールの使用 |
JP2009544007A (ja) | 2006-07-13 | 2009-12-10 | イェール・ユニバーシティー | バイオマーカーの細胞内局在性に基づいて癌予後を行う方法 |
WO2008032876A1 (fr) * | 2006-09-15 | 2008-03-20 | Tokai University | Médicament préventif et curatif pour le cancer du sein er négatif ou her2 négatif et méthode de criblage |
EP2094870A4 (en) | 2006-11-03 | 2010-05-05 | Univ Texas | BIFUNCTIONAL PREDICTORS FOR SENSITIVITY AND RESISTANCE TO ANTI-CANCER TREATMENT |
EP2518508A1 (en) | 2006-11-28 | 2012-10-31 | U3 Pharma GmbH | Activated HER3 as a marker for predicting therapeutic efficacy |
US7825127B2 (en) | 2006-12-28 | 2010-11-02 | Takeda Pharmaceutical Company, Limited | Method for treating cancer |
PT2716301T (pt) | 2007-02-16 | 2017-07-04 | Merrimack Pharmaceuticals Inc | Anticorpos contra erbb3 e suas utilizações |
BRPI0808418A2 (pt) | 2007-03-02 | 2014-07-22 | Genentech Inc | Predição de resposta a um inibidor de her |
EP2851091B1 (en) | 2007-04-13 | 2017-12-27 | Dana-Farber Cancer Institute, Inc. | Methods for treating cancer resistant to ERBB therapeutics |
WO2008138904A2 (en) | 2007-05-11 | 2008-11-20 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of her3 |
US20090054051A1 (en) | 2007-08-22 | 2009-02-26 | James Cavallo | Attachable Headset for Portable Device |
EA022201B1 (ru) | 2008-04-11 | 2015-11-30 | Мерримак Фармасьютикалз, Инк. | Агент, способный связываться с опухолевой клеткой, содержащий линкер на основе hsa, и его применение |
PE20120015A1 (es) * | 2008-08-15 | 2012-01-26 | Merrimack Pharmaceuticals Inc | Metodos y sistemas para predecir la respuesta de las celulas tumorales a un agente terapeutico |
WO2010059315A1 (en) | 2008-11-18 | 2010-05-27 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
EA201200195A1 (ru) | 2009-08-21 | 2012-12-28 | Мерримаск Фармасьютикалс, Инк. | АНТИТЕЛА ПРОТИВ ЭКТОДОМЕНА ErbB3 И ИХ ПРИМЕНЕНИЕ |
WO2011047180A1 (en) | 2009-10-14 | 2011-04-21 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof |
PL2544680T3 (pl) | 2010-03-11 | 2015-08-31 | Merrimack Pharmaceuticals Inc | Zastosowanie inhibitorów ERBB1 w leczeniu potrójnie ujemnego raka gruczołu sutkowego |
US8877687B2 (en) | 2010-04-26 | 2014-11-04 | Merrimack Pharmaceuticals | Assays for anti-drug antibodies in the presence of abundant endogenous protein counterpart of the drug |
EP2590654B1 (en) | 2010-07-09 | 2016-12-21 | Exelixis, Inc. | Combinations of kinase inhibitors for the treatment of cancer |
FR2963868B1 (fr) | 2010-08-11 | 2012-09-28 | Valeo Systemes Thermiques | Echangeur de chaleur comprenant un element chauffant serigraphie |
AU2011341337A1 (en) | 2010-12-10 | 2013-06-13 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of bispecific scFv conjugates |
AU2012222094A1 (en) | 2011-02-24 | 2013-10-10 | Merrimack Pharmaceuticals, Inc. | Combination therapies comprising anti-ErbB3 agents |
EA201300996A1 (ru) * | 2011-03-11 | 2014-01-30 | Мерримак Фармасьютикалс, Инк. | Использование ингибиторов рецепторов семейства egfr в лечении гормонорезистентного рака молочной железы |
EP2686015A2 (en) | 2011-03-15 | 2014-01-22 | Merrimack Pharmaceuticals, Inc. | Overcoming resistance to erbb pathway inhibitors |
JP5588086B2 (ja) | 2011-04-19 | 2014-09-10 | メリマック ファーマシューティカルズ インコーポレーティッド | 単一特異性および二重特異性抗IGF‐1R抗体および抗ErbB3抗体 |
CA2833554A1 (en) | 2011-05-06 | 2012-11-15 | Merrimack Pharmaceuticals, Inc. | Methods for preventing toxic drug-drug interactions in combination therapies comprising anti-erbb3 agents |
AU2012273361A1 (en) | 2011-06-24 | 2013-03-21 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of anti-ErbB3 antibodies in combination with paclitaxel |
KR20140063578A (ko) | 2011-06-30 | 2014-05-27 | 메리맥 파마슈티컬즈, 인크. | 부인과 암들의 치료를 위해 파크리탁셀과 조합한 항-erbb3 항체들 |
AU2012294326A1 (en) * | 2011-08-10 | 2013-03-21 | Merrimack Pharmaceuticals, Inc. | Treatment of advanced solid tumors using combination of anti-ErbB3 immunotherapy and selected chemotherapy |
MX2014011925A (es) | 2012-04-02 | 2015-05-11 | Merrimack Pharmaceuticals Inc | Dosificacion y administracion de anticuerpos monoespecíficos y biespecíficos anti- igf 1r y anti erbb3. |
WO2014036520A1 (en) | 2012-08-30 | 2014-03-06 | Merrimack Pharmaceuticals, Inc. | Combination therapies comprising anti-erbb3 agents |
WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
CA2975829A1 (en) | 2014-02-20 | 2015-09-03 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith |
-
2011
- 2011-03-11 PL PL11730112T patent/PL2544680T3/pl unknown
- 2011-03-11 SG SG2012063905A patent/SG183532A1/en unknown
- 2011-03-11 ES ES11730112.7T patent/ES2535503T3/es active Active
- 2011-03-11 MX MX2012010226A patent/MX344355B/es active IP Right Grant
- 2011-03-11 NZ NZ602084A patent/NZ602084A/en not_active IP Right Cessation
- 2011-03-11 JP JP2012557285A patent/JP2013522237A/ja active Pending
- 2011-03-11 CN CN201180013330.9A patent/CN102858335B/zh not_active Expired - Fee Related
- 2011-03-11 PT PT117301127T patent/PT2544680E/pt unknown
- 2011-03-11 US US13/583,949 patent/US8895001B2/en not_active Expired - Fee Related
- 2011-03-11 EP EP11730112.7A patent/EP2544680B1/en not_active Revoked
- 2011-03-11 CA CA2792327A patent/CA2792327C/en not_active Expired - Fee Related
- 2011-03-11 DK DK11730112T patent/DK2544680T3/en active
- 2011-03-11 EA EA201201186A patent/EA201201186A1/ru unknown
- 2011-03-11 KR KR1020127025753A patent/KR101798679B1/ko active IP Right Grant
- 2011-03-11 BR BR112012022802A patent/BR112012022802A2/pt not_active IP Right Cessation
- 2011-03-11 WO PCT/US2011/028129 patent/WO2011112953A2/en active Application Filing
- 2011-03-11 EP EP20140196121 patent/EP2859893A1/en not_active Ceased
- 2011-03-11 AU AU2011224186A patent/AU2011224186C1/en not_active Ceased
- 2011-11-03 UA UAA201210790A patent/UA111149C2/uk unknown
-
2012
- 2012-08-27 ZA ZA2012/06425A patent/ZA201206425B/en unknown
- 2012-08-30 IL IL221693A patent/IL221693A/en not_active IP Right Cessation
-
2013
- 2013-01-28 HK HK13101209.0A patent/HK1174254A1/xx not_active IP Right Cessation
-
2014
- 2014-10-20 US US14/518,900 patent/US9518130B2/en active Active
-
2016
- 2016-03-09 JP JP2016045111A patent/JP6185102B2/ja not_active Expired - Fee Related
- 2016-11-08 US US15/346,439 patent/US20170291957A1/en not_active Abandoned
-
2018
- 2018-05-31 US US15/994,393 patent/US20190119401A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX344355B (es) | Uso de inhibidores de erbb3 en el tratamiento de canceres de mama triple negativos y de tipo basal. | |
PH12017501500A1 (en) | Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy | |
MY183661A (en) | Treatment of cancer with tor kinase inhibitors | |
PH12014502048B1 (en) | Treatment of cancer with tor kinase inhibitors | |
MY180365A (en) | Markers of tumor cell response to anti-cancer therapy | |
MX2015017485A (es) | Uso de moleculas inhibidoras de semaforina-4d en combinacion con una terapia de modulacion inmune para inhibir crecimiento tumoral y metastasis. | |
MX367042B (es) | Combinacion de anticuerpos anti-kir y anticuerpos anti-dp-1 para tratar cancer. | |
PH12014502046A1 (en) | Treatment of cancer with tor kinase inhibitors | |
WO2012016133A3 (en) | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers | |
PH12014502029A1 (en) | Treatment of cancer with tor kinase inhibitors | |
MX2013010379A (es) | Uso de inhibidores de receptores de la familia egfr en el tratamiento de canceres de mama refractarios a hormonas. | |
MX2014011583A (es) | Metodos y composiciones para el tratamiento de la familia de tumores del sarcoma de ewing. | |
MX2020001727A (es) | Terapia de combinacion. | |
MX2013006319A (es) | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek. | |
PH12015500867A1 (en) | Treatment of prostate cancer with tor kinase inhibitors | |
TR201811308T4 (tr) | Kanser kok hücrelerini azaltan anti-emp2 tedavisi. | |
MX2018006776A (es) | Usos de pirimido-piridazinonas para tratar el cancer. | |
MX2012003287A (es) | Uso de la identificacion microambiental de sparc en el tratamiento del cancer. | |
TN2014000418A1 (en) | Methods for treating cancer using pi3k inhibitor and mek inhibitor | |
TN2013000247A1 (en) | Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer | |
UA35392U (ru) | Способ комплексной терапии злокачественных опухолей и метастазов | |
UA53221U (ru) | Способ комбинированного лечения рака слизистой оболочки ротовой полости |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |